BiologicalDrug
PEGylated carboxyhemoglobin bovine clinical trials
Also written SANGUINATE.
- studies test it
- 11
- open now
- 0
- in phase 3
- 1
- first study started
- 2013
How studies write it
Studies that test it under each name
Brand
Studies by the year they started
11 studies that test it; most in 2016 (5)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 5 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Prolong Pharmaceuticals (11)
Studies
Open first, then newest update. How each study uses PEGylated carboxyhemoglobin bovine is read from its arms, and is right about nine times in ten.
Testing it · 11
- Safety Study of PP-007 in Subjects With Acute Ischemic StrokeCompletedPhase 1Prolong PharmaceuticalsNCT04677777Written as PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)
- A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant PatientsWithdrawnPhase 2Prolong PharmaceuticalsNCT02658162Written as SANGUINATE
- A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease PatientsCompletedPhase 2Prolong PharmaceuticalsNCT02672540Written as SANGUINATE 320 mg/kg
- Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal DiseaseCompletedPhase 1Prolong PharmaceuticalsNCT02437422Written as SANGUINATE
- Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive CrisisCompletedPhase 2Prolong PharmaceuticalsNCT02411708Written as SANGUINATE
- A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.CompletedPhase 1Prolong PharmaceuticalsNCT02754999Written as SANGUINATE™
- SANGUINATE™ in Sickle Cell Disease Associated Leg UlcerCompletedPhase 2Prolong PharmaceuticalsNCT02600390Written as SANGUINATE
- Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney TransplantCompletedPhase 2/3Prolong PharmaceuticalsNCT02490202Written as SANGUINATE
- Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)CompletedPhase 2Prolong PharmaceuticalsNCT02323685Written as SANGUINATE™
- An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.TerminatedPhase 1Prolong PharmaceuticalsNCT01847222Written as SANGUINATE™
- Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) PatientsCompletedPhase 1Prolong PharmaceuticalsNCT01848925Written as SANGUINATE™